 CINCINNATI, June 28, 2021 GLOBE NEWSWIRE -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its application for Emergency Use Authorization EUA to the U.S. Food and Drug Administration FDA for the companys SARS-CoV-2 molecular diagnostic test on the Revogene platform. 